Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Document Type
Year range
FEBS Open Bio ; 12:314-315, 2022.
Article in English | EMBASE | ID: covidwho-1976632


Since the first days of the pandemic, diagnosis of patients infected with the SARS-CoV-2 has been one of the most important parameters to control the virus. For this reason, many studies have been carried out to develop various methods for rapid and accurate diagnosis, but mutations and the occurrence of successive variants have made accurate diagnosis difficult. In this study, a screen-printed carbon electrode was used to develop magnetic nanoparticle (MNP)-based electrochemical biosensing systems that selectively detect SARS-CoV-2 virus and its variants (original, alpha, beta, and delta) in nasopharyngeal swabs. These electrodes were modified with MNPs conjugated to SARS-CoV-2 S1, S2 proteins and swab samples. Then, commercially available SARS-CoV-2-specific anti-S1 and anti-S2 antibodies and antibody cocktails purified from serum samples were applied to the surface and the performance of the platforms was compared. Analytical parameters and electrode surface characterizations were performed by electrochemical measurements after each modification step. After optimization studies of the developed biosensor platforms, the detection of limit for the antibody cocktail- based sensors were determined to be 0.53-0.75 ng/mL, while it was calculated to be 0.93-0.99 ng/mL for the anti-S1 and anti- S2-based sensors. The performance of the platforms in real nasopharyngeal swab samples (negative, original, alpha, beta, and delta variants) was evaluated and it was found that the polyclonal antibody cocktail outperformed the commercial anti-S1 and anti-S2 antibodies. As a result, polyclonal antibody cocktail, with an overall sensitivity, specificity, and accuracy of 100%, is a versatile electrochemical biosensor system for the detection of the different variants of SARS-CoV-2. We hope that the biosensor platform modified with polyclonal antibodies can be used as a potential diagnostic tool that can be applied to such epidemics in the future. Synthetic biology.

Turkish Thoracic Journal ; 22(3):247-250, 2021.
Article in English | EMBASE | ID: covidwho-1264628


OBJECTIVE: To evaluate the clinical features and outcomes of patients who were admitted with a diagnosis of coronavirus disease 2019 (COVID-19) but who were not confirmed with polymerase chain reaction (PCR) positivity. MATERIAL AND METHODS: This is a retrospective analysis of all patients admitted to two tertiary care centers between March 15 and May 15, 2020, with a diagnosis of COVID-19. From a common database prepared for COVID-19, we retrieved the relevant data and compared the clinical findings and outcomes of PCR-positive patients with those of PCR-negative cases who had been diagnosed on the basis of typical clinical and radiographic findings. RESULTS: A total of 349 patients were included in the analysis, of which 126 (36.1%) were PCR-negative. PCR-negative patients were younger (54.6 ± 20.8 vs. 60.8 ± 18.9 years, P = .009) but were similar to PCR-positive patients in terms of demographics, comorbidities, and presenting symptoms. They had higher lymphocyte counts (1519 ± 868 vs. 1331 ± 737/mm3, P = .02) and less frequently presented with bilateral radiographic findings (68.3% vs. 79.4%, P = .046) than PCR-positive patients. Besides, they had less severe disease and better clinical outcomes regarding admission to the intensive care unit (9.6% vs. 20.6%, P = .023), oxygen therapy (21.4% vs. 43.5%, P < .001), ventilatory support (3.2% vs. 11.2%, P = .03) and length of hospital stay (5.0 ± 5.0 vs. 9.7 ± 5.9 days, P < .001). CONCLUSION: This study confirms that about one-third of the COVID-19 patients are PCR-negative and diagnosed based on clinicaand radiographic findings. These patients have a more favorable clinical course, shorter hospital stays, and are less frequently admitteto the intensive care unit.